Kura Oncology (KURA) Jefferies London Healthcare Conference 2025 summary

Key regulatory and clinical milestones

• Achieved FDA approval for a menin inhibitor in relapsed/refractory AML with NPM1 mutation, marking a significant advance in AML treatment after two decades.

• Label highlights four pillars: efficacy, safety, combinability, and convenience, with strong performance in each area compared to competitors.

• Safety profile distinguishes itself by avoiding a black box warning for QT prolongation, unlike the competitor, and shows a lower risk of sudden cardiac death.

• Ongoing and upcoming data presentations at ASH will provide further evidence in both frontline and relapsed/refractory settings.

• Randomized phase III trials are underway, with top-line results expected in 2028 to support accelerated approval pathways.

Market opportunity and launch strategy

• Total addressable market for NPM1 relapsed/refractory AML estimated at $350–$400 million, with a conservative 50% market share assumption.

• Frontline opportunity is projected to be 10–20 times larger, potentially reaching $10 billion annually at peak.

• Launch readiness is high, with commercial preparations completed and drug availability ensured shortly after approval.

• Initial sales are expected to be modest due to timing with holidays and ASH, but quarter-over-quarter growth is anticipated.

• Uptake is supported by strong physician interest and increased awareness from competitor activity.

Differentiation and clinical positioning

• Once-daily dosing and minimal drug-drug interactions offer advantages for elderly patients with comorbidities.

• Competitor's product carries a higher risk of QT prolongation and requires complex dosing adjustments due to CYP3A4 interactions.

• Emphasis on early combination therapy (triplet regimens) to optimize patient outcomes and avoid suboptimal sequencing.

• Data suggest higher rates of MRD negativity, reducing the need for transplant and supporting continuation therapy.

• Phase III trial design includes a three-arm study to secure a label for continuation therapy, unlocking further commercial potential.